Capricorn Fund Managers’s Xenon Pharmaceuticals XENE Stock Holding History

Capricorn Fund Managers’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26M	Buy	+20,900	New	+$1.16M	0.1%	134

Other funds holding XENE

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

SBI Okasan Asset Management Tokyo, Japan $3.04B AUM

Capricorn Fund Managers's XENE Position: Q2 2026 in Review

Capricorn Fund Managers opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 20,900 shares worth $1.26M. The stake represents 0.1% of the portfolio and ranks #134 among its holdings.

34 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Capricorn Fund Managers held 20,900 shares of Xenon Pharmaceuticals worth $1.26M as of Q2 2026.
Xenon Pharmaceuticals was a new Capricorn Fund Managers position in Q2 2026.
Xenon Pharmaceuticals made up 0.1% of Capricorn Fund Managers's portfolio in Q2 2026, its #134 holding.
34 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.